Related Experiment Videos
Neuroendocrine differentiation in prostatic carcinoma: an update
1University of Rochester Medical Center, New York 14642, USA. pdisantagnese@pathology.rochester.edu
The Prostate. Supplement
|August 5, 1998
Summary
Neuroendocrine differentiation in prostate cancer is linked to tumor growth and prognosis, particularly in androgen-insensitive types. Further research is needed to fully define its significance in prostatic carcinoma.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Neuroendocrine differentiation (NED) in prostatic carcinoma may influence prostate cancer growth and prognosis.
- This is especially relevant for androgen-insensitive prostate tumors.
Purpose of the Study:
- To review recent investigations on neuroendocrine differentiation in prostatic carcinoma.
- To build upon previous review articles and provide an updated perspective.
Main Methods:
- Systematic review of relevant publications on neuroendocrine differentiation in prostate cancer.
- Analysis of new developments, including receptor detection and the role of neuroendocrine products.
Main Results:
- New findings include detection of bombesin, calcitonin, and serotonin receptors.
- Neuroendocrine products influence prostate cancer growth, invasiveness, and motility.
- Prognostic significance appears greater in androgen-independent and metastatic tumors.
Conclusions:
- Neuroendocrine differentiation in prostatic carcinoma holds significant potential.
- Further definition is required to accurately assess its clinical significance.